Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: A high-throughput screening approach

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 2, 2010, Pages

  Chen, Wei ^a   Chen, Minyong ^a   Barak, Larry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

catenin; Dishevelled; Frizzled; Niclosamide; Receptor; Screening; Stem cells; Wnt

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; COLECOXIB; CPG 049090; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR; HARMINE; HEXACHLOROPHENE; NICLOSAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PKF 115; PROTEIN INHIBITOR; RESVERATOL; SULFONAMIDE; UNCLASSIFIED DRUG; XAV 939; ZMT 000990;

CANCER SCREENING; CANCER THERAPY; CANONICAL ANALYSIS; COLON CANCER; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG SCREENING; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTHELMINTICS; COLONIC NEOPLASMS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NICLOSAMIDE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77955635157     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00005.2010     Document Type: Review

References (59)

1. Ashburn TT, Gupta MS. The GERD market. Nat Rev Drug Discov 5: 277-278, 2006.
2. Barak LS, Ferguson SS, Zhang J, Martenson C, Meyer T, Caron MG. Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate. Mol Pharmacol 51: 177-184, 1997.
3. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
4. Cadigan KM, Peifer M. Wnt signaling from development to disease: insights from model systems (Abstract). Cold Spring Harb Perspect Biol 1: a002881, 2009.
5. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5: 100-107, 2009.
6. Chen M, Philipp M, Wang J, Premont RT, Garrison TG, Caron MG, Lefkowitz RJ, Chen W. G protein-coupled receptor kinases phosphorylate LRP6 in the Wnt pathway. J Biol Chem 284: 35040-35048, 2009.
7. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, Barak LS, Chen W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48: 10267-10274, 2009.
8. Chen W, Hu LA, Semenov MV, Yanagawa S, Kikuchi A, Lefkowitz RJ, Miller WE. β-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc Natl Acad Sci USA 98: 14889-14894, 2001.
9. Chen W, ten Berge D, Brown J, Ahn S, Hu LA, Miller WE, Caron MG, Barak LS, Nusse R, Lefkowitz RJ. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 301: 1391-1394, 2003.
10. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 129: 1614-1627, 2009.
11. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94, 2007.
12. Evers BM. Gastrointestinal growth factors and neoplasia. Am J Surg 190: 279-284, 2005.
13. Fuerer C, Nusse R, Ten Berge D. Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine meeting on Wnt signaling in Development and Disease. EMBO Rep 9: 134-138, 2008.
14. Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, Benovic JL. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383: 447-450, 1996.
15. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, Zhang Y, Alpatov I, Zhang XA, Lang RA, Shi DL, Zheng JJ. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284: 16256-16263, 2009.
16. Green DW, Roh H, Pippin JA, Drebin JA. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 101: 16-20, 2001.
17. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131: 1663-1677, 2004.
18. Hope C, Planutis K, Planutiene M, Moyer MP, Johal KS, Woo J, Santoso C, Hanson JA, Holcombe RF. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol Nutr Food Res 52, Suppl 1: S52-S61, 2008.
19. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-620, 2009.
20. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4, Suppl 2: S62-S68, 2004.
21. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21: 8414-8427, 2002.
22. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 59: 225-249, 2009.
23. Katoh M. WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets 9: 565-570, 2008.
24. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045, 2007.
25. Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol 3: 670-679, 2006.
26. Kiselyov AS, Tkachenko SE, Balakin KV, Ivachtchenko AV. Small-molecule modulators of Hh and Wnt signaling pathways. Expert Opin Ther Targets 11: 1087-1101, 2007.
27. Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG. The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem 275: 23120-23126, 2000.
28. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91-102, 2004.
29. Macdonald BT, Semenov MV, He X. SnapShot: Wnt/beta-catenin signaling. Cell 131: 1204, 2007.
30. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
31. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2: 329-337, 2006.
32. MacLachlan TK. In vino, curationis? Cancer Biol Ther 7: 1313-1314, 2008.
33. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290: 1574-1577, 2000.
34. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1255-1266, 2003.
35. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12: 575-625, 1996.
36. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
37. Moore WJ, Kern JC, Bhat R, Bodine PV, Fukyama S, Krishnamurthy G, Magolda RL, Pitts K, Stauffer B, Trybulski EJ. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg Med Chem 18: 190-201, 2010.
38. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 3: 18-29, 2007.
39. Park S, Gwak J, Cho M, Song T, Won J, Kim DE, Shin JG, Oh S. Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 70: 960-966, 2006.
40. Pelletier JC, Lundquist JT 4th, Gilbert AM, Alon N, Bex FJ, Bhat BM, Bursavich MG, Coleburn VE, Felix LA, Green DM, Green P, Hauze DB, Kharode YP, Lam HS, Lockhead SR, Magolda RL, Matteo JJ, Mehlmann JF, Milligan C, Murrills RJ, Pirrello J, Selim S, Sharp MC, Unwalla RJ, Vera MD, Wrobel JE, Yaworsky P, Bodine PV. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem 52: 6962-6965, 2009.
41. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407: 535-538, 2000.
42. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 67: 653-692, 1998.
43. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69: 511-534, 2007.
44. Ribas C, Penela P, Murga C, Salcedo A, Garcia-Hoz C, Jurado-Pueyo M, Aymerich I, Mayor F Jr. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta 1768: 913-922, 2007.
45. Salinas PC. Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway. Trends Cell Biol 17: 333-342, 2007.
46. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25: 7531-7537, 2006.
47. Semenov MV, Habas R, Macdonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. Cell 131: 1378.01-1378.02, 2007.
48. Rodrigues TA, Casimiro S, Gasparinho G, Crujo C, Matos M, Ruivo J, Fernandes A, Quintela A, Costa L. Involvement of chemokine receptors CXR4, CCR7, CCR6, and CXCR5 in colorectal cancer metastasis. Am Soc Clin Oncol Abstract 374: 2009.
49. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535, 2000.
50. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and- Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24: 394-400, 2006.
51. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 68: 1213-1220, 2008.
52. Van Amerongen R, Mikels A, Nusse R. Alternative wnt signaling is initiated by distinct receptors. Sci Signal 1: re9, 2008.
53. Waki H, Park KW, Mitro N, Pei L, Damoiseaux R, Wilpitz DC, Reue K, Saez E, Tontonoz P. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab 5: 357-370, 2007.
54. Wang L, Gesty-Palmer D, Fields TA, Spurney RF. Inhibition of WNT signaling by G protein-coupled receptor (GPCR) kinase 2 (GRK2). Mol Endocrinol 23: 1455-1465, 2009.
55. Wang PS, Chou FS, Bloomston M, Vonau MS, Saji M, Espinosa A, Pinzone JJ. Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells. J Surg Res 153: 210-216, 2009.
56. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A, DiNardo S. arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407: 527-530, 2000.
57. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL, Zheng J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 12: 1251-1260, 2003.
58. Yeh JR, Peterson RT. Novel Wnt antagonists target porcupine and Axin. Nat Chem Biol 5: 74-75, 2009.
59. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73, 1999.